Sotera Health Company currently trades at $17.92 per share and has shown little upside over the past six months, posting a small loss of 4.7%. The stock also fell short of the S&P 500’s 8% gain during that period.
Is there a buying opportunity in Sotera Health Company, or does it present a risk to your portfolio? Get the full breakdown from our expert analysts, it’s free.
Why Is Sotera Health Company Not Exciting?
We’re cautious about Sotera Health Company. Here are three reasons we avoid SHC, plus one stock we’d rather own.
1. Slow Organic Growth Suggests Waning Demand In Core Business
Investors interested in Research Tools & Consumables companies should track organic revenue in addition to reported revenue. This metric gives visibility into Sotera Health Company’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations – non-fundamental factors that can manipulate the income statement.
Over the last two years, Sotera Health Company’s organic revenue averaged 5% year-on-year growth. This performance slightly lagged the sector and suggests it may need to improve its products, pricing, or go-to-market strategy, which can add an extra layer of complexity to its operations. 
2. Fewer Distribution Channels Limit Its Ceiling
Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.
With just $1.19 billion in revenue over the past 12 months, Sotera Health Company is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.
3. Free Cash Flow Margin Dropping
Free cash flow isn’t a prominently featured metric in company financials and earnings releases, but we think it’s telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
As you can see below, Sotera Health Company’s margin dropped by 8.4 percentage points over the last five years. Almost any movement in the wrong direction is undesirable because of its already low cash conversion. If the trend continues, it could signal it’s becoming a more capital-intensive business. Sotera Health Company’s free cash flow margin for the trailing 12 months was 8.1%.
Final Judgment
Sotera Health Company isn’t a terrible business, but it doesn’t pass our bar. With its shares underperforming the market lately, the stock trades at 18× forward P/E (or $17.92 per share). Beauty is in the eye of the beholder, but our analysis shows the upside isn’t great compared to the potential downside. We’re pretty confident there are superior stocks to buy right now. We’d recommend looking at a dominant aerospace business that has perfected its M&A strategy.
Stocks We Would Buy Instead of Sotera Health Company
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
